Pharmerging Market

The global pharmerging market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing number of private hospitals and increasing healthcare expenditure.

Get Free Sample Report

Pharmerging is a term referred to a range of countries that have low or less development position in the pharmaceutical industry yet they have a fast income growth. Some of the main pharmerging markets are India, Brazil, Russia, China, Mexico, Indonesia, Turkey, and South Africa. The rise of population in these countries plays an important role in influencing the overall market growth. Additionally, growing the aging population acts as another main factor for the market expansion. Among every sixth person one person is expected to get over the age of 60 by 2030, as per a study by a global health organization. Geriatric population is expected to increase to 310 million by 2050 in China and crossing 275 million by 2050 in India. Most common diseases in the geriatric population include cardiac failure, hypertension, and dementia. These diseases require continuous and prolonged treatment. 

The demand for second care and home healthcare is rising among the geriatric population. There has been a rapid development in the healthcare facilities especially in major emerging economies such as Brazil, China, and India whereas these facilities are both privately as well as government funded. Governments across other countries have also increased healthcare expenditure and implemented supportive policies in order to decrease the cost of treatment for chronic diseases.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing number of private hospitals, increasing healthcare expenditure, and increasing number of chronic diseases are expected to boost the market growth in the coming years.
• Rising the geriatric population and gradual development of healthcare facilities especially the pharmaceutical industry are positively influencing the market growth.
• Availability of low-cost home healthcare system and expansion of several pharmaceutical manufacturing units in these countries are further expected to fuel the market expansion.
• Favorable government policies and healthcare initiatives to decrease the treatment cost for chronic diseases are expected to spur the market growth.
• Price sensitivity of the pharmaceutical products and lack of awareness for disease prevention or treatment are expected to hamper the market expansion during the forecast period.

Scope of the Report                          

The report on the global pharmerging market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Pharmaceutical segment is expected to grow at a rapid pace

Based on products, the global pharmerging market is bifurcated into pharmaceutical and other healthcare verticals. The pharmaceutical segment is further divided into OTC drugs, generic prescription drug, and patented prescription drugs, while the other healthcare verticals segment is sub-divided into clinical diagnostics, medical device, and others. The pharmaceutical segment is expected to grow at a rapid pace of the market in the coming years owing to rising healthcare expenditure and price sensitivity of pharmaceutical products. However, the other healthcare verticals segment is anticipated to expand at a healthy growth rate during the forecast period due to wide range of products and services available in the market for medical devices.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market during the projected period owing to rising demand of products and services by pharmaceutical vendors in the region. Meanwhile, the market of Asia Pacific is anticipated to expand at a high CAGR during the forecast period due to recent industry developments and supporting government policies in the region.

Get Free Sample Report

Segments

Segments Covered in the Report
The global pharmerging market has been segmented on the basis of
Applications

• Pharmaceutical
  • OTC Drugs
  • Generic Prescription Drug
  • Patented Prescription Drugs
• Other Healthcare Verticals
  • Clinical Diagnostics
  • Medical Device
  • Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Pfizer Inc.
• AstraZeneca Plc
• GlaxoSmithKline Plc
• SANOFI-Synthelabo (India) Private Limited
• F.Hoffmann-La Roche AG
• Eli Lilly and Company
• Medtronic
• Johnson and Johnson
• Abbott Healthcare
• GE Healthcare

Competitive Landscape

Key players competing in the pharmerging market are Pfizer Inc.; AstraZeneca Plc; GlaxoSmithKline Plc; SANOFI-Synthelabo (India) Private Limited; F.Hoffmann-La Roche AG; Eli Lilly and Company; Medtronic; Johnson and Johnson; Abbott Healthcare; and GE Healthcare.

Some of these main players are continuously engaged in various business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market positions. For instance, SANOFI-Synthelabo (India) Private Limited signed a transaction with Boehringer Ingelheim for the exchange of Sanofi’s animal health business and BI’s consumer healthcare business in January 2017.